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Abstract. Esophageal squamous cell carcinoma (ESCC) is 
the most predominantly occurring type of esophageal cancer 
worldwide. Locally advanced ESCC patients are treated by 
neoadjuvant chemoradiation for tumor downstaging prior to 
tumor resection. Patients receiving this treatment have an 
increased expectation of cure via the following tumor resection 
and have better survival outcomes. However, not all patients 
respond well to chemoradiation and poor responders suffer 
from treatment-associated toxicity and complications without 
benefits. No method is currently available to predict patient 
chemoradiation response and to exclude poor responders 
from ineffective treatment. To address this clinical limitation, 
the present study aimed to identify non-invasive biomarkers 
for predicting patient chemoradiation response. Due to the 
features of microRNA (miRNA) in cancer diagnosis, prog-
nosis and treatment response prediction, serum miRNA arrays 
were performed to identify potential miRNA(s) that may be 
used for chemoradiation response prediction in ESCC. Using 
an miRNA array to compare pre-treatment serum sample 
pools from 10 good responders and 10 poor responders, the 
present study identified miR‑193b, miR‑942 and miR‑629* as 
candidate miRNAs for predicting chemoradiation response. 
Subsequent validation using reverse transcription-quantitative 
polymerase chain reaction confirmed that miR‑193b, however 
not miR‑942 and miR‑629*, were significantly increased 
in sera from 24 good responders, compared with 23 poor 
responders. Further analyses using the receiver operating 
characteristic curve revealed a strong predictive power of 
serum miR‑193b on discriminating good responders from poor 
responders to chemoradiation. In addition, a high serum level 
of miR‑193b was significantly associated with better survival 
outcomes. Therefore, serum miR‑193b may be considered a 
promising biomarker for predicting chemoradiation response 
and post-therapy survival of ESCC patients.
Introduction
Esophageal cancer is the eighth most common cancer and the 
seventh leading cause of cancer-related death in men world-
wide (1). It is composed of two major types, i.e. esophageal 
squamous cell carcinoma (ESCC) and esophageal adenocarci-
noma. ESCC is the predominant type of esophageal cancer in 
Asian countries (2,3).
Tumor resection is the frontline treatment for ESCC 
patients. However, its benefit is limited to patients in early 
stage disease and those with resectable tumors. For patients 
with locally advanced tumors, they are alternatively treated 
with neoadjuvant chemoradiation for tumor down-staging 
before tumor resection. Based on the reports from our group 
and other research teams, such neoadjuvant treatment can 
enhance the chance of cure by tumor resection and therefore 
can profoundly increase patient outcomes (4-6). Despite 
that, patients exhibit a range of different responses towards 
chemoradiation from complete response, partial response to 
non-response. Till now, no clinical parameters or biomarkers 
are used to predict patient chemoradiation response and to 
identify non-responders to exclude them from treatment. 
Dismally, patients who do not respond to chemoradiation 
have to suffer from unnecessary and adverse side-effects of 
the treatment, such as drug-related toxicity and post-treatment 
complications. To address this clinical limitation, identification 
of biomarkers that can predict chemoradiation response can 
provide a guideline for selecting patients for chemoradiation, 
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such that responders will be offered chemoradiation and 
non-responders will be excluded from such treatment.
MicroRNAs (miRNAs) are single-stranded, non-coding 
small RNA of 19 to 25 nucleotides. With their main functions 
on regulating gene expressions, they are capable of regulating 
diversified cellular functions and are involved in a range of 
physiological processes of growth and development (7). 
However, their deregulation can be commonly found in various 
diseased conditions including cancer of various types (8). 
MiRNAs involve in tumorigenesis by functioning both as 
tumor suppressors and oncogenes. A number of miRNAs have 
been found to have deregulated expressions in tumors when 
compared to adjacent non-tumor tissues. These observations 
have implicated for the potential uses of miRNAs for cancer 
prognosis and therapy (7,9).
Apart from the uses of miRNAs for cancer prognosis and 
therapy, recent studies have started to investigate the capability 
of miRNAs to predict patient responses towards different 
anti-cancer treatments including chemotherapy and targeting 
therapy for various cancers including ESCC (10-14). Collectively, 
these findings have consolidated the use of miRNAs for 
treatment response prediction. Due to the secretory nature of 
miRNAs and their small sizes making them resistant to degra-
dation (15,16), current efforts have been focused on validating 
the use of circulatory miRNAs as non-invasive biomarkers for 
treatment response prediction for cancer patients (8,16,17).
The purpose of this study was to identify serum miRNAs 
that may serve as non-invasive biomarkers for treatment 
response prediction for ESCC patients. MiRNA array was 
employed in the analysis of serum samples from good 
responders vs. poor responders towards chemoradiation to 
identify candidate miRNAs with most differential differ-
ence in the serum levels between good responders and poor 
responders. The candidate miRNAs were further validated 
and analyzed for their potential use as predictive biomarkers 
for chemoradiation response of ESCC patients.
Materials and methods
Patient specimens. From 2000 to 2010, 47 locally advanced 
ESCC patients managed in Queen Mary Hospital, Hong Kong 
were included in this study. Age range of this patient cohort 
was 44 to 82 years old and the sex ratio was 44 (M) to 3 (F). 
All patients were treated with neoadjuvant cisplatin- and 
5-fluorouracil-based chemoradiation followed by tumor 
resection. Chemoradiation was given concurrently. The 
chemotherapy regimen composed of cisplatin at 100 mg/m2 
on day 1 and then day 22 and 5‑fluorouracil at 500 mg/m2 per 
day from day 1 to day 5 and day 22 to day 26. Radiotherapy 
was given at a dosage of 40Gy at 2Gy per fraction (18). Serum 
specimens were prepared from blood samples collected from 
patients before treatment with chemoradiation. Patient chemo-
radiation responses were determined pathologically based on 
the percentage of viable tumor cells in the resected tissues 
collected from tumor resection (18). In this study, patients with 
0% viable tumor cells were classified as good chemoradia-
tion responders, while those with at least 50% viable tumor 
cells were regarded as poor responders. Informed consent 
was obtained for each patient recruited in this study. AJCC 
6th edition was used for cancer staging. The use of clinical 
specimens for research was approved by the Institutional 
Review Board of The University of Hong Kong/Hospital 
Authority Hong Kong West Cluster (HKU/HA HKW IRB).
MiRNA array. Small RNAs from serum samples (10 samples 
from good responders and 10 samples from poor responders) 
were extracted using miRNeasy Serum/Plasma kit (Qiagen 
Inc., Hilden, Germany). RNA concentration and quality were 
determined using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). For both 
good responders and poor responders, pooled serum samples 
were prepared by mixing extracted RNAs from 5 samples, 
and that resulted in 2 serum sample pools for good responders 
and poor responders. The pooled RNA samples were then 
reverse transcribed to cDNA using TaqMan MicroRNA 
Reverse Transcription kit and Megaplex RT Primers (Applied 
Biosystems, Foster City, CA, USA) with the following thermal 
condition: 40 cycles of 16˚C for 2 min; 42˚C for 1 min; 50˚C for 
1 sec and 85˚C for 5 min. TaqMan Low Density Array (TaqMan 
Array Human MicroRNA A+B Cards Set v3.0; Applied 
Biosystems) was employed to generate miRNA profiles from 
754 different human miRNAs and U6, which was selected as 
an endogenous control. The reactions were performed in a 
7900HT Fast Real‑Time PCR System (Applied Biosystems), 
following the manufacturer protocol. Differentially expressed 
miRNAs were identified by comparing the miRNA profiles 
obtained from good responders and poor responders, and that 
miRNAs with at least 2.5-fold elevation in good responders vs. 
poor responders were subjected to further validation.
Reverse transcription‑quantitative polymerase chain reac‑
tion (RT‑qPCR). RNAs from serum specimens were prepared 
using miRNeasy Serum/Plasma kit (Qiagen). Concentration 
and quality of the extracted RNAs were determined as 
described above. To validate the miRNA array data, a TaqMan 
probe‑based RT‑qPCR system with the use of specific TaqMan 
MicroRNA Assays (Applied Biosystems) and TaqMan 
Fast Universal PCR Master Mix (Applied Biosystems) was 
performed on 24 good responders and 23 poor responders 
(including those used in the test cohort) (19-21). The reactions 
in duplicates were run on a 7900HT Fast Real‑Time PCR 
System (Applied Biosystems) under the following thermal 
cycling condition: 2 min at 50˚C; 10 min at 95˚C and 45 cycles 
of 15 sec at 95˚C and 1 min at 60˚C. U6 was used as an endog-
enous control. Relative expressions for the examined miRNAs 
were calculated using the ∆∆Cq method (22).
Statistical analyses. GraphPad Prism 6.0 (GraphPad Software, 
La Jolla, CA, USA) was used for statistical analyses. Quantitative 
data are described as the means with standard deviations (SD). 
Student's t-test was used to compare expression level difference of 
each miRNA (expressed as ∆∆Cq value) between studied groups. 
To assess the capability of the studied miRNA for discriminating 
good responders and poor responders towards chemoradiation, 
receiver operating characteristic (ROC) curve and the area under 
the ROC curve (AUC) with 95% confidence interval (CI) were 
generated (19,23). Survival was calculated by the Kaplan-Meier 
method from the date of operation to the time of death or last 
follow-up date. Log-rank test was used to compare survival 
difference between groups. Clinical categorical data were 
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analyzed using chi-squared test together with Pearson correla-
tion. P<0.05 was considered to indicate a statistically significant 
difference.
Results
Identification of candidate miRNAs for predicting patient 
chemoradiation responses. MiRNA array was performed 
on pooled serum samples from good responders and poor 
responders (Fig. 1). Of the 754 miRNAs examined, 37 
miRNAs had at least 2.5-fold elevation in sera from good 
responders when compared to poor responders, while 23 of 
them (highlighted in grey) displayed consistent data between 
the two serum sample pools from the same group (Table I). 
Three serum miRNAs (miR‑193b, miR‑942 and miR‑629*) 
with the most difference on the fold ratio between good 
responders and poor responders were selected as candidates 
for further validation (Fig. 2).
Figure 1. Study design to identify serum biomarkers to predict chemoradiation responses of ESCC patients. Two serum sample pools from 10 good responders 
and 10 poor responders towards chemoradiation were subjected to TaqMan Low Density Array to identify miRNA(s) with differential serum levels between 
these two studied groups. Three miRNAs with most differential difference in their serum levels in good responder group when compared to poor responder 
group were selected for further validation by RT-qPCR. ROC curve analyses were performed on the three selected miRNAs to evaluate their predictive powers 
for chemoradiation sensitivity.
Figure 2. Three miRNAs with most differential difference in serum levels between good responders and poor responders towards chemoradiation. MiRNA 
array result identified twenty‑three miRNAs with consistent data between two serum sample pools in the same group and with at least 2.5‑fold elevation in 
serum levels from good responders when compared to poor responders. MiR‑193b, miR‑942 and miR‑629* were the three miRNAs with most differential 
difference in their serum levels between good responders and poor responders.
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Validation of candidate miRNAs by RT‑qPCR. To validate 
the miRNA array data, RT‑qPCR on serum miR‑193b, 
miR‑942 and miR‑629* was performed on 24 good responders 
and 23 poor responders. The RT-qPCR results were 
consistent with those obtained by miRNA array, such that 
all three examined miRNAs demonstrated higher levels 
in sera from good responders when compared to poor 
responders (Fig. 3). However, only miR‑193b achieved a 
statistically significant result (P<0.05) (Fig. 3A). These results 
suggested that high serum level of miR‑193b could potentially 
be served as a biomarker to predict patient chemoradiation 
responses.
Serum miR‑193b serves as a non‑invasive predictive biomarker 
for patient chemoradiation response and survival outcome. To 
examine the predictive power of serum miR‑193b, miR‑942 
and miR‑629* on distinguishing good responders and poor 
responders towards chemoradiation, ROC curves analysis was 
Table I. Serum miRNAs with at least 2.5-fold elevation in good responders (GR) versus poor responders (PR).
 1st array 2nd array 1st array 2nd array   
 --------------- ----------------- --------------- ----------------- Relative level Relative level Fold ratio
miRNAs GR1 GR2 PR1 PR2 (GR) (PR) (GR/PR)
miR‑193ba 34.83 35.17 nd nd 0.3004 0.0368 8.1681
miR‑942a 34.03 36.31 nd nd 0.2544 0.0445 5.7160
miR‑629*a 35.03 35.44 nd nd 0.2432 0.0445 5.4642
miR‑99a* 34.94 nd nd 36.61 0.3132 0.0595 5.2598
miR‑510 nd 35.04 36.6 nd 0.2922 0.0597 4.8906
miR‑296‑5p 34.8 34.87 36.12 nd 0.3368 0.0706 4.7733
miR‑624*a 34.97 35.98 nd nd 0.2059 0.0445 4.6268
miR‑486‑3pa 34.17 34.78 36.32 37.56 0.4118 0.0928 4.4383
miR‑149 33.89 35.37 35.48 nd 0.3882 0.0881 4.4076
miR‑1266a 35.29 36.1 nd nd 0.1768 0.0445 3.9724
miR-7a 34.81 35.14 36.49 37.25 0.3057 0.0805 3.7974
miR‑603 nd 33.65 nd nd 0.1615 0.0445 3.6301
miR‑188‑5p nd 34.47 nd nd 0.1276 0.0368 3.4702
miR‑490‑3p 34.17 30.59 32.61 35.67 1.8468 0.5340 3.4581
miR‑29c*a 35.89 36.04 nd 38 0.1466 0.0445 3.2944
miR‑501‑5p 33.77 35.79 nd 34.93 0.3499 0.1066 3.2830
miR‑548c‑5pa 35.01 37.07 nd nd 0.1392 0.0445 3.1275
miR‑17*a 34.5 37.59 nd nd 0.1387 0.0445 3.1167
miR‑451a 20.23 21.1 22.48 21.98 6208.3751 2055.1101 3.0209
miR‑650a 35.01 37.22 nd nd 0.1321 0.0445 2.9690
miR‑92aa 24.97 25.08 26.61 26.5 302.3341 102.5369 2.9485
miR‑340a 37.07 35.9 nd nd 0.1073 0.0368 2.9180
miR‑891a nd 34.98 nd nd 0.1069 0.0368 2.9079
miR‑885‑5p 36.11 35.02 36.08 nd 0.2031 0.0715 2.8382
miR‑19ba 25.61 26.35 27.29 27.57 155.9565 55.9087 2.7895
miR‑18a*a 32.67 33.65 34.95 34.25 1.0755 0.3882 2.7702
miR‑16a 23.72 24.28 25.55 25.33 615.2377 222.0899 2.7702
miR-122a 30.57 29.55 31.26 31.74 9.2215 3.3288 2.7702
let-7ba 28.18 28.66 29.64 29.96 28.7402 10.8153 2.6574
miR-500a 34.39 35.29 36.38 36.06 0.3356 0.1263 2.6574
miR-25a 28.08 28.8 29.98 29.64 28.3446 10.7406 2.6390
miR‑765 36.39 35.97 nd 37.09 0.1326 0.0504 2.6299
miR‑200a nd 35.79 nd 37.14 0.1737 0.0668 2.6027
miR-215a 32.69 33.68 33.91 35.16 1.0570 0.4061 2.6027
miR‑625* 35.45 35.07 35.21 nd 0.2509 0.0967 2.5937
miR‑92b 35.49 36.07 nd 36.23 0.1749 0.0679 2.5758
miR‑22*a 34.05 33.68 34.72 35.66 0.6598 0.2579 2.5580
nd, not detectable. amiRNAs with consistent data between two arrays in the same group.
ONCOLOGY LETTERS  15:  3273-3280,  2018 3277
performed to obtain the AUC values and 95% CI. ROC curve data 
of serum miR‑193b revealed a strong predictive power to distin-
guish good responders and poor responders (AUC: 0.8949, 95% 
CI: 0.7912‑0.9987, P<0.0001) (Fig. 4A). Although ROC curve 
analysis supporting the use of serum miR‑942 for distinguishing 
good responders and poor responders (AUC: 0.6727, 95% CI: 
0.5156‑0.8298, P=0.0428) (Fig. 4B), serum miR‑942 failed to 
demonstrate significant difference between its level in good 
responders and poor responders (Fig. 3B). On the other hand, 
serum miR‑629* failed to show sufficient discriminative power 
to distinguish good responders from poor responders (Fig. 4C). 
Based on the differential difference of serum miR‑193b 
level in good responders vs. poor responders and the good 
discriminative power of serum miR‑193b on distinguishing 
good responders from poor responders, our data have supported 
the potential use of miR‑193b for predicting chemoradiation 
response.
Figure 3. Higher level of serum miR‑193b in good responders when compared to poor responders towards chemoradiation. Among the three miRNAs with most 
differential difference in their serum levels between good responders and poor responders, only miR‑193b (A), but not miR‑942 (B) and miR‑629* (C), showed 
statistically significant difference in its serum level between good responders and poor responders. Error bars represent the standard deviation; **P<0.01.
Figure 4. Serum miR‑193b as the most powerful biomarker for predicting chemoradiation sensitivity for ESCC patients. ROC curve analyses were performed 
on miR‑193b (A), miR‑942 (B) and miR‑629* (C) to evaluate their predictive power for chemoradiation sensitivity in ESCC patients. Both serum miR‑193b and 
miR‑942 showed a statistically significant difference.
Figure 5. High serum level of miR‑193b associated with better patient 
survivals. Kaplan‑Meier survival curves for 47 ESCC patients were 
constructed. Log-rank test showed a statistically significant difference 
between low miR‑193b level and high miR‑193b level groups (P=0.0099). 
**P<0.01.
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As miR‑193b is a potential predictor for chemoradiation 
response in ESCC patients, we also performed survival and 
clinical analyses by using the median value as a cut-off value to 
divide the patients into two groups with high and low serum level 
of miR‑193b. Patients with high serum miR‑193b level associ-
ated better survival (median survival=71.5 months) than those 
with low serum miR‑193b level (median survival=16 months) 
(P=0.0099) (Fig. 5). High serum miR‑193b level was inversely 
correlated with post-therapy pathological ypT stage (P<0.001), 
ypN stage (P=0.045), ypM stage (P=0.035) and overall 
ypTNM stage (P<0.001) (Table II). Moreover, high serum 
miR‑193b level was associated with R0 category (no residual 
tumor after surgery) (P<0.001) and with pathological complete 
response (ypCR) (P<0.001) (Table II). Collectively, our data 
have suggested that high serum level of miR‑193b can poten-
tially serve as a non-invasive predictive biomarker for patient 
chemoradiation response and survival outcome.
Discussion
Neoadjuvant chemoradiation followed by tumor resection 
has become the standard treatment for locally advanced 
ESCC (24-26). However, patients respond differently towards 
such neoadjuvant treatment. On average, only 20-30% of 
patients demonstrate complete chemoradiation response. Poor 
responders, on the other hand, suffer unnecessary chemoradia-
tion‑related toxicity and complications without benefits. In view 
of this clinical situation, identification of reliable biomarker 
that can predict patient response before chemoradiation is 
important for selecting optimal treatment for patients.
For ESCC, previous studies have proposed the use of 
several biomarkers identified from ESCC tumors to predict 
patient chemoradiation response. A study has demonstrated 
the association of excision repair cross-complementing 1 
(ERCC1) with cisplatin response in ESCC by revealing 
tumoral ERCC1 levels in patients with partial responses 
to chemoradiation were significantly lower than those in 
non-responsive patients. Besides, ESCC cell lines with lower 
ERCC1 level showed greater sensitivity to clinically relevant 
concentrations of cisplatin and its related drug oxaliplatin 
when compared to cell lines with higher ERCC1 level (27). 
In addition to this single molecule study, a number of studies 
have taken into accounts the use of more than one molecule 
for predicting chemoradiation responses. Using cDNA 
microarray to analyze pre-chemoradiation tumor biopsies 
from ESCC patients has identified a 32‑gene classifier that 
Table II. Clinical correlation analyses of serum miR‑193b level in ESCC patients treated with neoadjuvant chemoradiation.
  Serum miR‑193b level
  ----------------------------------------------
Clinicopathological parameters Patient number High Low P-value
Age (years)    
  ≤64.5 23 10 13 0.308
  >64.5 24 14 10 
Gender    
  Male 44 24 20 0.067
  Female 3 0 3 
R category    
  R0 34 24 10 <0.001
  R1/R2 13 0 13 
Pathological stage    
  ypT stage    
    ypT0 24 21 3 <0.001
    ypT1/2 4 0 4 
    ypT3/4 19 3 16 
  ypN stage    
    ypN0 33 20 13 0.045
    ypN1 14 4 10 
  ypM stage    
    ypM0 40 23 17 0.035
    ypM1 7 1 6 
  ypTNM    
    ypCRa 24 21 3 <0.001
  y‑stage I/II 9 1 8 
  y‑stage III/IV 14 2 12
aPathological complete response.
ONCOLOGY LETTERS  15:  3273-3280,  2018 3279
can be used to predict patient responses towards chemo-
radiation (28). Another study by Wen et al has carried out 
gene expression analysis on pre-treatment ESCC biopsies 
from patients who have received neoadjuvant chemora-
diation followed by surgery. Based on the gene expression 
analysis, they have developed a prediction model composing 
of three genes (MMP1, LIMCH1 and C1orf226) that can 
be used to predict pathological response towards chemo-
radiation with high accuracy (29). Apart from the above 
use of protein-coding genes for predicting chemoradiation 
responses of ESCC patients, research has also been focused 
on exploring the potential use of non-coding RNAs for this 
purpose. MiRNAs are non‑coding RNAs with diversified 
roles on tumor progression and development, implicating 
their plausible uses for cancer classification and prognostica-
tion (7,30). By analyzing the pre-treatment tumor biopsies, a 
recent miRNA study has identified the combined use of four 
differentially expressed miRNAs (miR‑145‑5p, miR‑152, 
miR‑193b‑3p and miR‑376a‑3p) for chemoradiation response 
prediction for ESCC patients (14).
When compared to the biomarkers derived from ESCC 
tumors, blood-based biomarkers are better predictors for 
chemotherapy/chemoradiation responses of patients as the 
procedure for blood collection is minimally invasive. Most 
studies on finding blood-based biomarkers for chemo-
therapy/chemoradiation response prediction put the focus 
on miRNAs because of their stability in human circula-
tion (15,16). Kurashige et al have reported the use of serum 
miR-21 for indicating chemotherapy response by showing a 
significant reduction of its serum level in ESCC patients who 
are responsive to chemotherapy, but not in non-responders, 
after treatment (31). On the other hand, Tanaka et al have 
demonstrated serum level of miR-200c can be used for 
predicting chemotherapy responses for ESCC patients 
receiving chemotherapy (32). In the current study, we identi-
fied serum miR‑193b by miRNA array, and validated it as 
a reliable predictor for chemoradiation responses for ESCC 
patients using TaqMan probe‑based qPCR. Specifically, high 
serum level of miR‑193b can indicate ESCC patients who are 
responsive to chemoradiation. Moreover, high serum level of 
miR‑193b was significantly associated with better survival 
and inversely correlated with post-therapy pathological 
stages. Despite the advantageous feature of miRNAs, some 
studies have alternatively investigated the possible use of 
other circulatory protein or mRNA for predicting chemora-
diation responses. Maher et al have utilized proteomics to 
analyze pre-treatment sera from esophageal cancer patients 
and have revealed significant elevation on the serum levels 
of complement C4a and C3a in poor responders towards 
chemoradiation (33). Moreover, a more recent study has also 
demonstrated the usefulness of circulating FAM84B mRNA 
and protein for predicting pathological chemoradiation 
responses (34). The above studies have supported the idea of 
using circulating biomarkers for predicting chemoradiation 
responses of ESCC patients.
In this study, we have reported high serum miR‑193b level 
in ESCC patients responsive to chemoradiation, implicating 
the link between miR‑193b and chemoradiation sensitivity. 
Similarly, Nyhan et al have reported the positive asso-
ciation between miR‑193b and increased chemosensitivity of 
esophageal cancer cells, such that overexpression of miR‑193b 
in chemoresistant esophageal cancer cells sensitized them 
towards chemotherapeutic drug treatment (35). Apart from the 
direct link between miR‑193b with chemotherapy/chemora-
diation sensitivity, this miRNA is proven to involve in other 
treatment-related sensitivities. In melanoma, over-expression 
of miR‑193b in ABT‑737‑resistant tumor cells can restore their 
sensitivity towards ABT-737 (BH3 mimetic) treatment (36). In 
another scenario, over‑expression of miR‑193b in liver cancer 
cells can sensitize them towards treatment with molecular 
targeting drug sorafenib (37). Together, these prior studies 
including the current one depict the importance of miR‑193b 
on determining the treatment sensitivity of tumor cells and 
implicate the potential of restoring miR‑193b for treatment 
sensitization.
In summary, the present study has demonstrated high 
level of serum miR‑193b as a promising biomarker for 
predicting chemoradiation responses and post-therapy 
survival of ESCC patients. Further validation on a larger 
and independent patient cohort is required for full assess-
ment of its predictive power. Our findings can benefit the 
treatment selection process for locally advanced ESCC patients 
by predicting their sensitivities towards chemoradiation, such 
that only good responders will be offered this treatment.
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